What is the purpose of this trial?
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care.
Actinium Pharmaceuticals Inc.
Dates: 07/17/2017 - 04/01/2018
Last Updated: 07/19/2017
Study HIC#: 1607018056